Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Other financing activities: 2022-2023

Historic Other financing activities for Madrigal Pharmaceuticals (MDGL) over the last 1 years, with Sep 2023 value amounting to $75,000.

  • Madrigal Pharmaceuticals' Other financing activities was N/A to $75,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $1.2 million, marking a year-over-year change of. This contributed to the annual value of $363,000 for FY2023, which is 59.03% down from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Other financing activities of $75,000 as of Q3 2023, which was down 0.00% from $75,000 recorded in Q2 2023.
  • Madrigal Pharmaceuticals' Other financing activities' 5-year high stood at $886,000 during Q2 2022, with a 5-year trough of $75,000 in Q2 2023.
  • In the last 2 years, Madrigal Pharmaceuticals' Other financing activities had a median value of $144,000 in 2023 and averaged $312,250.
  • Data for Madrigal Pharmaceuticals' Other financing activities shows a maximum YoY plummeted of 91.53% (in 2023) over the last 5 years.
  • Quarterly analysis of 2 years shows Madrigal Pharmaceuticals' Other financing activities stood at $886,000 in 2022, then plummeted by 91.53% to $75,000 in 2023.
  • Its last three reported values are $75,000 in Q3 2023, $75,000 for Q2 2023, and $213,000 during Q1 2023.